An official website of the United States government
A .mil website belongs to an official U.S. Department of Defense organization in the United States.
A lock (lock ) or https:// means you’ve safely connected to the .mil website. Share sensitive information only on official, secure websites.

 








 
181 - 192 of 8444 results
Thumbnails List
Frederick, MD
FREDERICK, Md. (April 11, 2025) Researchers with Biological Defense Research Directorate (BDRD), pose for a group photo after conducting bacteriophage therapy research to combat multidrug resistant bacteria that could impact warfighter readiness. Phages are viruses that target and kill antibiotic-resistant bacteria. Navy Medicine Research & Development (NMR&D) is engaged in bacteriophage therapy research to protect the warfighter from these threats, keeping U.S. forces ready and lethal. NMRC, headquarters of NMR&D, is engaged in a broad spectrum of activity from basic science in the laboratory to field studies in austere and remote areas of the world to investigations in operational environments. In support of Navy, Marine Corps and joint U.S. warfighter health, readiness and lethality, researchers study infectious diseases, biological warfare detection and defense, combat casualty care, environmental health concerns, aerospace and undersea medicine, operational mission support and epidemiology. For 250 years, Navy Medicine, represented by more than 44,000 highly-trained military and civilian healthcare professionals, has delivered quality healthcare and enduring expeditionary medical support to the warfighter on, below, and above the sea and ashore. (U.S. Navy photo by Elliott Page /Released)
Frederick, MD
FREDERICK, Md. (April 11, 2025) Dr. Biswajit Biswas, chief of Bacteriophage Science Division with Naval Medical Research Command (NMRC), inspects a purified phage sample as part of bacteriophage therapy research to combat multidrug resistant bacteria that could impact warfighter readiness. Phages are viruses that target and kill antibiotic-resistant bacteria. Navy Medicine Research & Development (NMR&D) is engaged in bacteriophage therapy research to protect the warfighter from these threats, keeping U.S. forces ready and lethal. NMRC, headquarters of NMR&D, is engaged in a broad spectrum of activity from basic science in the laboratory to field studies in austere and remote areas of the world to investigations in operational environments. In support of Navy, Marine Corps and joint U.S. warfighter health, readiness and lethality, researchers study infectious diseases, biological warfare detection and defense, combat casualty care, environmental health concerns, aerospace and undersea medicine, operational mission support and epidemiology. For 250 years, Navy Medicine, represented by more than 44,000 highly-trained military and civilian healthcare professionals, has delivered quality healthcare and enduring expeditionary medical support to the warfighter on, below, and above the sea and ashore. (U.S. Navy photo by Elliott Page /Released)
Frederick, MD
FREDERICK, Md. (April 11, 2025) Dr. Biswajit Biswas, chief of Bacteriophage Science Division with Naval Medical Research Command (NMRC), inspects a purified phage sample as part of bacteriophage therapy research to combat multidrug resistant bacteria that could impact warfighter readiness. Phages are viruses that target and kill antibiotic-resistant bacteria. Navy Medicine Research & Development (NMR&D) is engaged in bacteriophage therapy research to protect the warfighter from these threats, keeping U.S. forces ready and lethal. NMRC, headquarters of NMR&D, is engaged in a broad spectrum of activity from basic science in the laboratory to field studies in austere and remote areas of the world to investigations in operational environments. In support of Navy, Marine Corps and joint U.S. warfighter health, readiness and lethality, researchers study infectious diseases, biological warfare detection and defense, combat casualty care, environmental health concerns, aerospace and undersea medicine, operational mission support and epidemiology. For 250 years, Navy Medicine, represented by more than 44,000 highly-trained military and civilian healthcare professionals, has delivered quality healthcare and enduring expeditionary medical support to the warfighter on, below, and above the sea and ashore. (U.S. Navy photo by Elliott Page /Released)
Frederick, MD
FREDERICK, Md. (April 11, 2025) Dr. Biswajit Biswas, chief of Bacteriophage Science Division with Naval Medical Research Command (NMRC), inspects a purified phage sample as part of bacteriophage therapy research to combat multidrug resistant bacteria that could impact warfighter readiness. Phages are viruses that target and kill antibiotic-resistant bacteria. Navy Medicine Research & Development (NMR&D) is engaged in bacteriophage therapy research to protect the warfighter from these threats, keeping U.S. forces ready and lethal. NMRC, headquarters of NMR&D, is engaged in a broad spectrum of activity from basic science in the laboratory to field studies in austere and remote areas of the world to investigations in operational environments. In support of Navy, Marine Corps and joint U.S. warfighter health, readiness and lethality, researchers study infectious diseases, biological warfare detection and defense, combat casualty care, environmental health concerns, aerospace and undersea medicine, operational mission support and epidemiology. For 250 years, Navy Medicine, represented by more than 44,000 highly-trained military and civilian healthcare professionals, has delivered quality healthcare and enduring expeditionary medical support to the warfighter on, below, and above the sea and ashore. (U.S. Navy photo by Elliott Page /Released)
Frederick, MD
FREDERICK, Md. (April 11, 2025) Naval Medical Research Command (NMRC), conducts bacteriophage therapy research to combat multidrug resistant bacteria that could impact warfighter readiness. Phages are viruses that target and kill antibiotic-resistant bacteria. Navy Medicine Research & Development (NMR&D) is engaged in bacteriophage therapy research to protect the warfighter from these threats, keeping U.S. forces ready and lethal. NMRC, headquarters of NMR&D, is engaged in a broad spectrum of activity from basic science in the laboratory to field studies in austere and remote areas of the world to investigations in operational environments. In support of Navy, Marine Corps and joint U.S. warfighter health, readiness and lethality, researchers study infectious diseases, biological warfare detection and defense, combat casualty care, environmental health concerns, aerospace and undersea medicine, operational mission support and epidemiology. For 250 years, Navy Medicine, represented by more than 44,000 highly-trained military and civilian healthcare professionals, has delivered quality healthcare and enduring expeditionary medical support to the warfighter on, below, and above the sea and ashore. (U.S. Navy photo by Elliott Page /Released)
Frederick, MD
FREDERICK, Md. (April 11, 2025) Naval Medical Research Command (NMRC), conducts bacteriophage therapy research to combat multidrug resistant bacteria that could impact warfighter readiness. Phages are viruses that target and kill antibiotic-resistant bacteria. Navy Medicine Research & Development (NMR&D) is engaged in bacteriophage therapy research to protect the warfighter from these threats, keeping U.S. forces ready and lethal. NMRC, headquarters of NMR&D, is engaged in a broad spectrum of activity from basic science in the laboratory to field studies in austere and remote areas of the world to investigations in operational environments. In support of Navy, Marine Corps and joint U.S. warfighter health, readiness and lethality, researchers study infectious diseases, biological warfare detection and defense, combat casualty care, environmental health concerns, aerospace and undersea medicine, operational mission support and epidemiology. For 250 years, Navy Medicine, represented by more than 44,000 highly-trained military and civilian healthcare professionals, has delivered quality healthcare and enduring expeditionary medical support to the warfighter on, below, and above the sea and ashore. (U.S. Navy photo by Elliott Page /Released)
Frederick, MD
FREDERICK, Md. (April 11, 2025) Researchers with Naval Medical Research Command (NMRC) conduct bacteriophage therapy research to combat multidrug resistant bacteria that could impact warfighter readiness. Phages are viruses that target and kill antibiotic-resistant bacteria. Navy Medicine Research & Development (NMR&D) is engaged in bacteriophage therapy research to protect the warfighter from these threats, keeping U.S. forces ready and lethal. NMRC, headquarters of NMR&D, is engaged in a broad spectrum of activity from basic science in the laboratory to field studies in austere and remote areas of the world to investigations in operational environments. In support of Navy, Marine Corps and joint U.S. warfighter health, readiness and lethality, researchers study infectious diseases, biological warfare detection and defense, combat casualty care, environmental health concerns, aerospace and undersea medicine, operational mission support and epidemiology. For 250 years, Navy Medicine, represented by more than 44,000 highly-trained military and civilian healthcare professionals, has delivered quality healthcare and enduring expeditionary medical support to the warfighter on, below, and above the sea and ashore. (U.S. Navy photo by Elliott Page /Released)
Frederick, MD
FREDERICK, Md. (April 11, 2025) Researchers with Naval Medical Research Command (NMRC) conduct bacteriophage therapy research to combat multidrug resistant bacteria that could impact warfighter readiness. Phages are viruses that target and kill antibiotic-resistant bacteria. Navy Medicine Research & Development (NMR&D) is engaged in bacteriophage therapy research to protect the warfighter from these threats, keeping U.S. forces ready and lethal. NMRC, headquarters of NMR&D, is engaged in a broad spectrum of activity from basic science in the laboratory to field studies in austere and remote areas of the world to investigations in operational environments. In support of Navy, Marine Corps and joint U.S. warfighter health, readiness and lethality, researchers study infectious diseases, biological warfare detection and defense, combat casualty care, environmental health concerns, aerospace and undersea medicine, operational mission support and epidemiology. For 250 years, Navy Medicine, represented by more than 44,000 highly-trained military and civilian healthcare professionals, has delivered quality healthcare and enduring expeditionary medical support to the warfighter on, below, and above the sea and ashore. (U.S. Navy photo by Elliott Page /Released)
Frederick, MD
FREDERICK, Md. (April 11, 2025) Naval Medical Research Command (NMRC), conducts bacteriophage therapy research to combat multidrug resistant bacteria that could impact warfighter readiness. Phages are viruses that target and kill antibiotic-resistant bacteria. Navy Medicine Research & Development (NMR&D) is engaged in bacteriophage therapy research to protect the warfighter from these threats, keeping U.S. forces ready and lethal. NMRC, headquarters of NMR&D, is engaged in a broad spectrum of activity from basic science in the laboratory to field studies in austere and remote areas of the world to investigations in operational environments. In support of Navy, Marine Corps and joint U.S. warfighter health, readiness and lethality, researchers study infectious diseases, biological warfare detection and defense, combat casualty care, environmental health concerns, aerospace and undersea medicine, operational mission support and epidemiology. For 250 years, Navy Medicine, represented by more than 44,000 highly-trained military and civilian healthcare professionals, has delivered quality healthcare and enduring expeditionary medical support to the warfighter on, below, and above the sea and ashore. (U.S. Navy photo by Elliott Page /Released)
Frederick, MD
FREDERICK, Md. (April 11, 2025) Researchers with Naval Medical Research Command (NMRC) conduct bacteriophage therapy research to combat multidrug resistant bacteria that could impact warfighter readiness. Phages are viruses that target and kill antibiotic-resistant bacteria. Navy Medicine Research & Development (NMR&D) is engaged in bacteriophage therapy research to protect the warfighter from these threats, keeping U.S. forces ready and lethal. NMRC, headquarters of NMR&D is engaged in a broad spectrum of activity from basic science in the laboratory to field studies in austere and remote areas of the world to investigations in operational environments. In support of Navy, Marine Corps and joint U.S. warfighter health, readiness and lethality, researchers study infectious diseases, biological warfare detection and defense, combat casualty care, environmental health concerns, aerospace and undersea medicine, operational mission support and epidemiology. For 250 years, Navy Medicine, represented by more than 44,000 highly-trained military and civilian healthcare professionals, has delivered quality healthcare and enduring expeditionary medical support to the warfighter on, below, and above the sea and ashore. (U.S. Navy photo by Elliott Page /Released)
Frederick, MD
FREDERICK, Md. (April 11, 2025) Researchers with Naval Medical Research Command (NMRC) conduct bacteriophage therapy research to combat multidrug resistant bacteria that could impact warfighter readiness. Phages are viruses that target and kill antibiotic-resistant bacteria. Navy Medicine Research & Development (NMR&D) is engaged in bacteriophage therapy research to protect the warfighter from these threats, keeping U.S. forces ready and lethal. NMRC, headquarters of NMR&D, is engaged in a broad spectrum of activity from basic science in the laboratory to field studies in austere and remote areas of the world to investigations in operational environments. In support of Navy, Marine Corps and joint U.S. warfighter health, readiness and lethality, researchers study infectious diseases, biological warfare detection and defense, combat casualty care, environmental health concerns, aerospace and undersea medicine, operational mission support and epidemiology. For 250 years, Navy Medicine, represented by more than 44,000 highly-trained military and civilian healthcare professionals, has delivered quality healthcare and enduring expeditionary medical support to the warfighter on, below, and above the sea and ashore. (U.S. Navy photo by Elliott Page /Released)
Conkry, Guinea
CONKARY, Guinea. (Feb. 24, 2025) Dr. Alia Zayed, with Naval Medical Research Unit (NAMRU) EURAFCENT, leads a session on mosquito identification techniques with Guinean military and health personnel. The initiative is part of the Vector Biology Research Program, which provides valuable insights into disease transmission risks, enabling U.S. forces to better prepare for deployment in environments with high level of endemic diseases. NAMRU EURAFCENT, part of Navy Medicine Research & Development, conducts research, surveillance and studies of vaccines, therapeutic agents, diagnostic assays and vector control measures in the EUCOM, AFRICOM and CENTCOM Areas of Responsibility to better prevent and treat infectious diseases in support of Navy, Marine Corps and joint U.S. warfighter health, readiness and lethality. For 250 years, Navy Medicine, represented by more than 44,000 highly-trained military and civilian healthcare professionals, has delivered quality healthcare and enduring expeditionary medical support to the warfighter on, below, and above the sea and ashore. (U.S. Navy photo by Lt. Cmdr. Matt Montgomery/Released)
BUMED Seal


Bureau of Medicine and Surgery
7700 Arlington Blvd. Ste. 5113 Falls Church, VA 22042-5113
This is an official U.S. Navy website
This is a Department of Defense (DoD) Internet computer system.

General Navy Medical Inquiries (to Bureau of Medicine and Surgery): usn.ncr.bumedfchva.list.bumed---pao@health.mil
 


Charlie Mike Flags
 

Facebook Icon   Twitter  Instagram  YouTube  LinkedIn  Flickr Internet Archive
Safe Helpline
Veterans Crisis Line
Northern Command: Dial 988 then Press 1
Pacific Command: Call +1 844-702-5493 (off base) or DSN 988 (on base)
European Command: Call +1 844-702-5495 (off base) or DSN 988 (on base)
Central Command: Call +1 855-422-7719 (off base) or DSN 988 (on base)
African Command: Call +1 888-482-6054 (off base) or DSN 988 (on base)
Southern Command: Call +1 866-989-9599 (off base) or DSN 988 (on base)
Guidance-Card-Icon Dept-Exclusive-Card-Icon